13 recruiting, 8 unknown, 5 completed, 4 withdrawn. 17 Phase 1, 14 Phase 2, 3 Early Phase 1, 2 Not applicable, 1 Phase 4.
Follow Multiple Myeloma, Refractory: new trials by email Literature Review of Multiple Myeloma, Refractory trials Research Report on Multiple Myeloma, Refractory
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Evaluate the Safety of UF-KURE-BCMA CAR T-Cells in Advanced Myeloma Administration of CAR T-cells at 3 different dose levels - Multiple Myeloma in Relapse, Multiple Myeloma, Refractory | Phase 1 | Not yet recruiting | Kure Cells, INC | 12 | 2026-09-01 | 2026-05-28 |
| Recombinant Human IL-7 (NT-I7) in Relapsed/Refractory Multiple Myeloma Following BCMA CAR-T Therapy (Cilta-cel) NT-I7, Placebo - Multiple Myeloma, Multiple Myeloma in Relapse | Phase 1 | Recruiting | Washington University School of Medicine | 52 | 2026-06-05 | 2026-10-15 |
| UF-KURE-BCMA CAR-T Cells in Patients With Relapsed or Refractory Multiple Myeloma UF-KURE-BCMA CAR T-cells, Cyclophosphamide, Fludarabine - Multiple Myeloma, Multiple Myeloma in Relapse | Phase 1 | Withdrawn | David Wald | 2025-09-01 | 2026-05-13 | |
| HCMT/MM2401: Ph2 Study of Selinexor + Bispecific Antibody for RRMM Selinexor 40 mg - Multiple Myeloma in Relapse, Multiple Myeloma, Refractory | Phase 2 | Recruiting | Duke University | 27 | 2025-08-22 | 2026-09-03 |
| Sequential CAR-T Cells Targeting BCMA/GPRC5D in Patients With Relapsed/ Refractory Multiple Myeloma BCMA/GPRC5D CAR-T cells - Multiple Myeloma, Multiple Myeloma in Relapse | Phase 1 / Phase 2 | Recruiting | Essen Biotech | 60 | 2025-04-29 | 2025-06-22 |
| Universal CAR-T Cell Therapy for MM Targeted BCMA Gene-Modified Allogeneic Chimeric Antigen Receptor T-Cell Injection - Multiple Myeloma, Multiple Myeloma in Relapse | Not applicable | Recruiting | Bioray Laboratories | 6 | 2025-04-10 | 2025-12-01 |
| A Phase I Study to Assess the Tolerability of 225Ac-DOTATATE in Patients With Refractory and Relapsing Multiple Myeloma Expressing Somatostatin Receptors 225Ac-DOTATATE - Multiple Myeloma, Refractory, Multiple Myeloma in Relapse | Phase 1 | Withdrawn | Jules Bordet Institute | 2024-10-01 | 2025-01-31 | |
| A Trial of Selinexor, Ruxolitinib and Methylprednisolone Selinexor, Ruxolitinib, Methylprednisolone - Multiple Myeloma in Relapse, Multiple Myeloma, Refractory | Phase 1 | Recruiting | Oncotherapeutics | 30 | 2024-08-06 | 2025-01-16 |
| Early Palliative Care for Patients With Multiple Myeloma and Aggressive Lymphoma Early Palliative Care - Multiple Myeloma in Relapse, Multiple Myeloma, Refractory | Not applicable | Recruiting | University Health Network, Toronto | 144 | 2024-07-18 | 2025-12-03 |
| A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma Venetoclax - Multiple Myeloma in Relapse, Multiple Myeloma, Refractory | Phase 2 | Recruiting | Oncotherapeutics | 39 | 2024-06-20 | 2025-01-16 |
| Anti-BCMA CAR-NK Therapy in Relapsed or Refractory Multiple Myeloma Anti-BCMA CAR-NK - Multiple Myeloma, Refractory | Phase 1 / Phase 2 | Unknown | Shahid Beheshti University of Medical Sciences | 10 | 2024-04-30 | 2024-03-06 |
| LMY-920 for Treatment of Relapsed or Refractory Myeloma Autologous CAR-T cell therapy expressing the BAFF-ligand. - Multiple Myeloma, Refractory, Multiple Myeloma in Relapse | Phase 1 | Recruiting | Luminary Therapeutics | 30 | 2024-03-13 | 2024-10-18 |
| Marizomib Central Nervous System (CNS) Marizomib, Pomalidomide, Dexamethasone - Multiple Myeloma, Multiple Myeloma in Relapse | Phase 2 | Withdrawn | Dana-Farber Cancer Institute | 2024-03-01 | 2024-07-16 | |
| A Phase I Trial to Establish the Safety and Maximum Tolerated Dose of High-affinity Autologous BCMA-targeting Chimeric Antigen Receptor (CAR) T-cells in Patients With Relapsed and Refractory B-cell Malignancies MDC-CAR-BCMA001 (BCMA directed CAR T-cells) - Neoplasms, Relapsed Diffuse Large B-cell Lymphoma (DLBCL) | Phase 1 | Recruiting | Technische Universität Dresden | 16 | 2024-02-15 | 2026-08-27 |
| All-trans Retinoic Acid in Combination With a KPD Regimen for the Treatment of Refractory/Relapsed Multiple Myeloma All-trans Retinoic Acid in combination with the KPD Regimen - Multiple Myeloma in Relapse, Multiple Myeloma, Refractory | Phase 2 | Recruiting | The First Affiliated Hospital of Xiamen University | 25 | 2023-11-22 | 2025-02-19 |
| Carfilzomib, Oral Cyclophosphamide, and Dexamethasone for RRMM Carfilzomib, Cyclophosphamide, Dexamethasone - Multiple Myeloma in Relapse, Multiple Myeloma, Refractory | Phase 2 | Not yet recruiting | Dong-A University Hospital | 49 | 2023-07-01 | 2023-06-18 |
| Safety and Efficacy of Anti-GPRC5D CAR-T Cells Therapy in the Treatment of r/r MM Anti-GPRC5D CAR-T Cells Injection - Multiple Myeloma in Relapse, Multiple Myeloma, Refractory | Phase 1 / Phase 2 | Unknown | XuYan | 18 | 2023-04-10 | 2023-04-20 |
| Impact of a Health Technology Intervention on Patient Activation in Multiple Myeloma Multiple Myeloma in Relapse, Multiple Myeloma | Active not recruiting | All4Cure | 200 | 2023-03-01 | 2025-09-04 | |
| Safety and Efficacy of Anti-GPRC5D CAR-T Cells Therapy in the Treatment of r/r MM Anti-GPRC5D CAR-T cells infusion - Multiple Myeloma in Relapse, Multiple Myeloma, Refractory | Phase 1 / Phase 2 | Unknown | 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China | 18 | 2023-02-07 | 2023-02-23 |
| Alternative Dosing Scheme of Pomalidomide 4 mg Every Other Day Versus Pomalidomide 2 mg and 4 mg Every Day; the POMAlternative Study Pomalidomide 4 mg every day in cycle 1, Pomalidomide 4 mg every other day in cycle 2, Pomalidomide 2 mg every day in cycle 2 - Multiple Myeloma in Relapse, Multiple Myeloma | Phase 4 | Completed | Amsterdam UMC, location VUmc | 12 | 2022-12-01 | 2025-04-22 |
Showing 20 of 35. Sign in to see all of them.
Multiple Myeloma (35) · Lymphoma, Large B-Cell, Diffuse (2) · Recurrence (2) · Autoimmune Diseases (1) · Carcinoma, Hepatocellular (1) · Lymphoma, B-Cell (1) · Lymphoma, Non-Hodgkin (1) · Neoplasms (1) · Neoplasms, Plasma Cell (1) · Patient Participation (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1)
Blood Protein Disorders (35) · Cardiovascular Diseases (35) · Hematologic Diseases (35) · Hemic and Lymphatic Diseases (35) · Hemorrhagic Disorders (35) · Hemostatic Disorders (35) · Immune System Diseases (35) · Immunoproliferative Disorders (35) · Lymphoproliferative Disorders (35) · Neoplasms by Histologic Type (35) · Paraproteinemias (35) · Vascular Diseases (35) · Neoplasms (34) · Neoplasms, Plasma Cell (34) · Lymphatic Diseases (4)
Dexamethasone (8) · Cyclophosphamide (4) · carfilzomib (4) · pomalidomide (4) · Calcium Dobesilate (3) · selinexor (3) · Bortezomib (2) · fludarabine (2) · pembrolizumab (2) · Cyclosporine (1) · Dasatinib (1) · LNA-i-miR-221 (1) · Lenalidomide (1) · Methylprednisolone (1) · Tretinoin (1)
Dong-A University Hospital (2) · Oncotherapeutics (2) · Zhejiang University (2) · 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China (1) · Ajai Chari (1) · Alfred Chung, MD (1) · All4Cure (1) · Amsterdam UMC, location VUmc (1) · Azienda Ospedaliera Universitaria Mater Domini, Catanzaro (1) · Bioray Laboratories (1) · Chongqing Precision Biotech Co., Ltd (1) · Dana-Farber Cancer Institute (1) · David Wald (1) · Duke University (1) · Epizyme, Inc. (1)
United States (13) · China (9) · Israel (2) · Belgium (1) · Canada (1) · France (1) · Germany (1) · Greece (1) · Iran (1) · Italy (1) · Netherlands (1)
James Berenson, MD (2) · Sung-Hyun Kim, MD, Ph.D (2) · Ajai Chari, MD (1) · Alfred Chung, MD (1) · Breffni Hannon, MB BCh BAO, MMedSci, MCFP (1) · Clifton Mo, MD (1) · James Ignatz-Hoover, MD, PhD (1) · Leland Metheny, MD (1) · Mani Ramzi, Prof. (1) · Martin Wermke, Prof. (1) · Michael Slade, M.D., M.S.C.I (1) · Noa Biran, MD (1) · Pierfrancesco Tassone, MD (1)
PMID 10613347, PMID 27511158, PMID 30592986, PMID 32055000, PMID 35190680, PMID 36762851, PMID 37272512, PMID 37365583, PMID 38826786
2017 (1)